Nom du produit:tert-butyl (2-hydroxyethyl)(isopropyl)carbamate

IUPAC Name:tert-butyl N-(2-hydroxyethyl)-N-(propan-2-yl)carbamate

CAS:610309-73-4
Formule moléculaire:C10H21NO3
Pureté:95%+
Numéro de catalogue:CM1020214
Poids moléculaire:203.28

Unité d'emballage Stock disponible Prix($) Quantité

Pour une utilisation en R&D uniquement..

Formulaire de demande

   refresh    

Détails du produit

N° CAS:610309-73-4
Formule moléculaire:C10H21NO3
Point de fusion:-
Code SMILES:CC(C)N(CCO)C(=O)OC(C)(C)C
Densité:
Numéro de catalogue:CM1020214
Poids moléculaire:203.28
Point d'ébullition:
N° Mdl:
Stockage:

Category Infos

Aliphatic Chain Compounds
Aliphatic chain compounds include aliphatic compounds and chain compounds containing other elements or groups. Aliphatic hydrocarbons are hydrocarbons with the basic properties of aliphatic compounds. In aliphatic compounds, carbon atoms are arranged in straight chain, branched chain or cyclic, which are respectively called straight chain aliphatic hydrocarbons, branched chain aliphatic hydrocarbons and alicyclic hydrocarbons. Some cyclic hydrocarbons are different in nature from aromatic hydrocarbons, and are very similar to aliphatic hydrocarbons. Such cyclic hydrocarbons are called alicyclic hydrocarbons. In this way, aliphatic hydrocarbons become a general term for all hydrocarbons except aromatic hydrocarbons. Aliphatic hydrocarbons and their derivatives (including halogenated hydrocarbons) and alicyclic hydrocarbons and their derivatives are collectively referred to as aliphatic compounds.

Column Infos

XRD-0394
XRad Therapeutics announced that the first patient has been dosed in the company’s Phase 1a trial evaluating XRD-0394 in combination with radiation therapy for the treatment of metastatic, locally-advanced or recurrent solid tumors.
XRD-0394, is a first-in-class dual inhibitor of ataxia-telangiectasia mutated (ATM) and DNA-dependent protein kinase (DNA-PK). Initial development efforts are focused on evaluating XRD-0394’s ability to enhance radiation therapy when used in combination. In parallel, the company is exploring the potential benefits of using XRad’s dual kinase inhibitors in combination with targeted radionuclides, immune checkpoint inhibitors, polyadenosine diphosphate-ribose polymerase inhibitors and antibody drug conjugates.

Related Products